Fast Facts

8 – 12 March 2023

Brisbane Convention and Exhibition Centre

1,200+ attendees

3 days main program + 2 days pre-congress program

For all sponsor and exhibition enquiries contact:
Thomas Howden

Secretariat Industry Liaison
c/o MCI Australia
T:  +61 2 9213 4016
E: thomas.howden@wearemci.com

© 2023 ORL-HNS 2023. All Rights Reserved.

Inclusions Principal Partner
(2 Opportunities)
Major Partner
(8 Opportunities)
Supporting Partner
(Multiple)
$48,000
Incl GST
$36,000
Incl GST
$24,000
Incl GST
Audience Engagement
Lunch symposium
Breakfast seminar
Exhibition booth


(27sqm)


(18sqm)


(9sqm)

Promotion of one hosted off-site function (function hosted by partner at partner expense)
Delegate Experience
Sponsor profile and logo on the congress website + app
200 words
200 words
150 words
Acknowledgement of sponsor level on all congress marketing and promotion materials
Advertising banner on congress EDMs (max 3 banners per EDM)
2
1
1
Advertisement (full page) congress app
Verbal sponsor acknowledgement during opening and closing address
Sponsor logo on congress holding slide
App notification/popup (once per day, per user)
Registrations
Congress delegate registrations
4
3
2
Exhibition/staff registrations
8
5
3
Tickets to the welcome reception
8
5
3
Tickets to the gala dinner
8
5
3
Delegate list (first and last name, organisation and country. Subject to GDPR and privacy laws) 14 days prior, 7 days prior and within one week post-congress
Industry program attendance data (app-based scanning + viewership metrics)
Exhibition lead tracking technology (app-based QR-code. Exportable leads and notes)
Individual Partner Items
Audience Engagement
Breakfast seminar
$16,000 (Available to Major Partners or stand-alone)
Women in otolaryngology, trainee and new fellows lunch
$15,000 (Exclusive)
Controversies in otolaryngology debate
$15,000 (Exclusive)
Instructional course
Price on application (Multiple)
Gala dinner
$12,000 (Exclusive)
Mentorship roundtable (trainee + established mentor groups)
$15,000 (Exclusive per day)
Promotion of hosted off-site function
$4,000 (Multiple)
Delegate Experience
Congress app (exclusive)
$10,000
Delegate lanyards (exclusive)
$10,000
Exhibition lounge (exclusive)
$8,000
Exhibition seating (exclusive)
$10,000
Social media wall (foyer)
$8,000
Advertising and Promotion
Registration desk
$7,500
Decal advertisement (x1 in exhibition)
$3,000
Pre-congress advertising
Advertising banner on promotional EDMs
Partner acknowledgement (website listing)

$3,500 (max 3 banners per EDM)
$4,000
During congress advertising
Advertising banner on highlights EDMs (each day of congress)
Congress app advertisement (full page)

$3,500 (max 3 banners per EDM)
$3,000 (Multiple)
Post-congress advertising
Advertising banner on thank you EDM

$3,500 (max 3 banners)

Dr Seiji Kakehata

Yamagata University Faculty of Medicine

Seiji Kakehata, M.D., Ph.D.is best known for his work in pioneering endoscopic ear surgery in his home country of Japan and around the world. He servesas Professor and Chair of the Department of Otorhinolaryngology-Headand Neck Surgery at Yamagata University Faculty of Medicine. He is the Chair of Board of Directors, Japan Otological Society (JOS). In addition, he is a founding board member of the International Working Group on Endoscopic Ear Surgery(IWGEES) and its presidentelectas well as the president of the Pan-Asia Working Group on Endoscopic Ear Surgery (PAWGEES).

Dr. Kakehata’s clinical interests includeminimally invasive endoscopicear surgery, conductive and sensorineural hearing loss,and facial nervepalsy.Dr. Kakehata’s research has focused on cochlear hair cell physiology and hearing regeneration. His funded research includes the study of outer hair cell motility, effects of cholesterol alterationson outer hair cells, regenerationof the facial nerve, and regeneration of auditory nerve fiber growth and synapse formation after ear injury.

Dr. Kakehata organized and held the first courses in endoscopic earsurgery in Asia and has held anannual hands-on course since 2012. He has presented at numerous regionaland national meetings in Japan as well as international meetings and courses especially on the subject of endoscopic ear surgery. He has published approximately 150 articles and book chapters.

Dr Dana Thompson

Ann & Robert H. Lurie Children’s Hospital of Chicago

MD, MS, MBA, FACS

Dr. Thompson is the Lauren D. Holinger Professor Chair of Pediatric Otolaryngology at the Ann & Robert H. Lurie Children’s Hospital of Chicago and Northwestern University Feinberg School of Medicine. She has held faculty positions as premier institutions including the Mayo Clinic and University of Cincinnati College of Medicine/Cincinnati Children’s Hospital. In 2011 she achieved the academic rank of Professor, making her the first African American woman professor in the specialty of Otolaryngology Head and Neck Surgery in the United States. She brings 23 years of experience as an internationally recognized airway surgeon and leader in aerodigestive medicine. The collective research contributions in laryngomalacia have influenced the surgical and medical management of the disease and she is considered one of the world’s authorities on the topic. She received the prestigious Mosher Award from the Triological Society for excellence in clinical research for her seminal work elucidating the etiology of Laryngomalacia.

Prof Sarah Wise

Emory University School of Medicine

Sarah K. Wise, MD, MSCR is Professor of Otolaryngology-Head and Neck Surgery at Emory University in Atlanta, Georgia. She is the Emory Otolaryngology Residency Program Director, Rhinology Fellowship Director, and Director of Otolaryngic Allergy. Dr. Wise completed medical school at the University of Texas Health Science Center San Antonio, residency at Emory University and rhinology fellowship at the Medical University of South Carolina. Dr. Wise has served on the Board of Directors of the American Rhinologic Society and the American Academy of Otolaryngic Allergy. She will become President of the American Rhinologic Society in September 2022, serving as the Society’s first female president. Her clinical interests include inflammatory rhinology, otolaryngic allergy, relationship of allergy and chronic rhinosinusitis, and cerebrospinal fluid leaks. Dr. Wise lectures nationally and internationally. Her most notable publication is the International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis, where she served as first author/primary editor.

Name

Company

Lorem ipsum dolor sit amet. Aut officia facilis sit animi voluptatum ut voluptatem nisi rem omnis quia. Vel libero minima et totam officia non rerum sequi sunt impedit sit aliquid neque rem mollitia sint non iste voluptatum. Et distinctio sequi aut voluptatem provident in maxime esse cum velit quia a asperiores harum in error deserunt qui repellat vero. Ut voluptatem animi et voluptates quidem ut rerum dolor aut libero perspiciatis.

Prof Robert Ferris

UPMC Hillman Cancer Center

Robert L. Ferris, MD, PhD is Hillman Professor of Oncology and Director of the UPMC Hillman Cancer Center. He is Associate Vice Chancellor for Cancer Research, and Professor of Otolaryngology, of Immunology, and of Radiation Oncology at the University of Pittsburgh. As a head and neck surgical oncologist and translational tumor immunologist, his lab is uniquely positioned to investigate mechanisms of anti-tumor immunity in the tumor microenvironment (TME), as well as tumor cell
escape. Dr. Ferris’s NIH-funded laboratory is focused on reversal of immune escape and immunotherapy using monoclonal antibodies and vaccines, leading to the first positive randomized phase III trial of head and cancer immunotherapy. He is Principal Investigator of the Pitt Specialized Program of Research Excellence (SPORE) grant for translational head and neck research and has been continuously NIH R01 funded for >15 years.

Dr. Ferris has an h-index of 96 and his >420 peer-reviewed scientific and clinical publications have garnered >36,000 citations. Dr. Ferris currently serves on the Editorial Boards of JNCI, JCO, Clinical Cancer Research, and Cancer Immunology Research. He is Editor in Chief of Oral Oncology. He is lead investigator of several practice-changing, prospective randomized trials, including Checkmate-141 published in NEJM, which led to the FDA approval of Nivolumab for head and neck cancer, ECOG 3311 (published in JCO in late 2021), testing radiation dose-deintensification after transoral robotic surgery (TORS) for HPV+ oropharynx cancer, as well as ECOG ACRIN 3132, using p53 mutational testing in HPVnegative cancer, to predict response to radiation versus chemoradiation. He recently completed a 6-year term co-chairing  the NCI Steering Committee for Head and Neck Cancer and is currently Vice President of the American Head and Neck Society.

Sponsor Name

Sponsor bio – Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Contact